Medidata Launches Global Education Program for Study Build and Study Management Professionals
Medidata has launched Rave EDC Certified Study Builder certification, a new offering in its global education program for study build and study management professionals. The Rave EDC Certified Study Builder Program offers a guided learning path to certification for new and existing Rave study builders, and includes core skills and applied skills assessments.
Study builders can expect a guided learning path, including:
- an instructor-led prep course to facilitate successful certification
- an abbreviated path enabling Classic Rave Certified Study Builders to upgrade their certification without the need to retake core Rave EDC training
Study Builders then complete an expanded core skills exam and applied skills assessment using a mock study build. Successful completion ends with a digital badge recognizing proficiency in Rave EDC study design and build, clinical view data settings, clinical view data review, and the use of Rave Reporter.
Reference
Global Medidata Certification Model Helps Rave EDC Study Builders Create New Value for Their Companies. (2023, March 23). Business Wire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
